| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/24/2003 | WO2003007782A3 Biodegradable injectable implants and related methods of manufacture and use |
| 04/24/2003 | WO2003004049A3 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 04/24/2003 | WO2002102376A8 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT |
| 04/24/2003 | WO2002098907A3 Cation conducting gabaa receptors and their use |
| 04/24/2003 | WO2002096353A3 Polymer controlled induced viscosity fiber system and uses thereof |
| 04/24/2003 | WO2002094744A3 Compositions comprising d-chiro inositol and sulfonylureas and methods of treatment thereof |
| 04/24/2003 | WO2002089741A3 Compositions and methods for enhancing drug delivery |
| 04/24/2003 | WO2002088343A3 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT) |
| 04/24/2003 | WO2002088180A3 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 04/24/2003 | WO2002076509A3 Preparation for the prophylaxis of restenosis |
| 04/24/2003 | WO2002072822A3 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 04/24/2003 | WO2002069979A3 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | WO2002056875A3 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 04/24/2003 | WO2002053137A3 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 04/24/2003 | WO2002051988A3 Thymic epithelial progenitor cells and uses thereof |
| 04/24/2003 | WO2002046383A3 Protein modification and maintenance molecules |
| 04/24/2003 | WO2002045710A9 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 04/24/2003 | WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 04/24/2003 | WO2002024180A3 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 04/24/2003 | WO2002016615A3 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 04/24/2003 | WO2002014554A3 The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| 04/24/2003 | WO2002004513A3 Down syndrome critical region 1-like 1 proteins |
| 04/24/2003 | WO2001075440A3 Schizophrenia related genes |
| 04/24/2003 | US20030078541 Device for injection of antiparasitic agents in pets |
| 04/24/2003 | US20030078532 Composite dressings for the treatment of wounds |
| 04/24/2003 | US20030078418 Useful potentiators of beta -lactam antibiotics; therapy |
| 04/24/2003 | US20030078409 Nucleotide sequences coding polypeptide for use in the treatment of respiratory system, asthmatic and inflammatory bowel diseases |
| 04/24/2003 | US20030078376 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 04/24/2003 | US20030078373 Chaperone fragments |
| 04/24/2003 | US20030078304 Administering to animal or man of at least one type of xanthophyll in an amount inhibiting the expression of inflammatory cytokines and chemokines in animal or man |
| 04/24/2003 | US20030078303 Methods of treating and preventing sexual dysfunction using (+) sibutramine in combination with phosphodiesterase inhibitors |
| 04/24/2003 | US20030078302 As carriers for delivering active agents such as peptides, drugs by administration, such as oral, subcutaneous, sublingual, and intranasal administration |
| 04/24/2003 | US20030078293 Administering etodolac for therapy of prostate cancer in a mammals |
| 04/24/2003 | US20030078281 Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
| 04/24/2003 | US20030078275 For therapy of cancer, diabetes and Alzheimer's disease |
| 04/24/2003 | US20030078274 Method of reducing neuronal injury or apoptosis |
| 04/24/2003 | US20030078266 Powder of 30-90% a water-soluble cycloxygenase inhibitor, 5-60% of a buffer and 0-10% of other excipients |
| 04/24/2003 | US20030078257 Methods of treating tumors |
| 04/24/2003 | US20030078252 Used to treat abnormal cell growth and central nervous system disorders |
| 04/24/2003 | US20030078246 Combinations for the treatment of inflammatory disorders |
| 04/24/2003 | US20030078241 Treating effects of excessive reactive oxygen species |
| 04/24/2003 | US20030078214 Phytooestrogen selected from genistein, daidzein; for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia |
| 04/24/2003 | US20030078212 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 04/24/2003 | US20030078200 Treating a DSM-III disorder by administering to a mammal a peptide or a peptidomimetic thereof to reduce or eliminate symptoms of the DSM-III disorder |
| 04/24/2003 | US20030078196 Administering cisplatin; drug delivery; reduced dosage to prevent release into systemic circulation |
| 04/24/2003 | US20030078190 Methods for tissue protection using highly effective inhibition of the renin-angiotensin system |
| 04/24/2003 | US20030078166 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | US20030077750 Peptide for use in human therapeutics and diagnostics |
| 04/24/2003 | US20030077749 Ucp5 |
| 04/24/2003 | US20030077734 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 04/24/2003 | US20030077665 Detection of nervous system modulators; obtain preferential nervous system tissue in vitro, culture, incubate with modulator, monitor and evaluate adjustment in cell activity |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077628 Detection of preferential binding particles; obtain ligand sample, incubate with liquid crystal solution, expose to spectrum analysis, compare to control, monitor binding activity |
| 04/24/2003 | US20030077624 Diagnosing cancer in mammals; obtain sample cells, monitor expression of collapsin protein, amplified concentration of collapsin indicates cancer |
| 04/24/2003 | US20030077592 Methods for analyzing LTC4 synthase polymorphisms and diagnostic use |
| 04/24/2003 | US20030077571 Model for use in evaluation and treatment of muscular disorders and asthenopia |
| 04/24/2003 | US20030077568 Screening drugs; obtain cell with preferential phenotypic profile, incubate with drug, monitor effect on cells |
| 04/24/2003 | US20030077564 Amplification of neural cell viability in brain or spinal cord tissue after brain or spinal cord injury; obtain tissue, apply nutrient broth, monitor cell viability |
| 04/24/2003 | US20030077335 Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| 04/24/2003 | US20030077333 Diarrhea therapy; gel mouth rehydration solution |
| 04/24/2003 | US20030077327 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | US20030077323 Amoxicillin - clarithromycin antibiotic composition |
| 04/24/2003 | US20030077321 Complex containing tannin; solid dosage form; sustained release |
| 04/24/2003 | US20030077313 Anti-stress composition intended for incorporation mainly in nutritional vehicles |
| 04/24/2003 | US20030077307 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 04/24/2003 | US20030077305 Administering to a mammal a formualtion comprising cationic lipids/DNA complex, allowing the complex to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time such that the complex enters the target cells |
| 04/24/2003 | US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli |
| 04/24/2003 | US20030077285 Methods of diagnosis and treatment by binding p75/airm1 |
| 04/24/2003 | US20030077279 Methods for treating vascular disease by inhibiting toll-like receptor-4 |
| 04/24/2003 | US20030077273 Methods of treating antibody-mediated pathologies using agents which inhibit CD21 |
| 04/24/2003 | US20030077258 Comprising one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue and nerve graft |
| 04/24/2003 | US20030077247 Chemokines as adjuvants of immune response |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030077242 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 04/24/2003 | US20030077236 An enzyme extract use as sunscreen agent, able degrading melanin |
| 04/24/2003 | CA2466800A1 Modulation of ocular growth and myopia by gaba drugs |
| 04/24/2003 | CA2466082A1 Anti-microbial composition comprising a metal ion chelating agent |
| 04/24/2003 | CA2463991A1 Therapeutic composition and use |
| 04/24/2003 | CA2463927A1 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 04/24/2003 | CA2463925A1 Bone anti-resorptive compounds |
| 04/24/2003 | CA2463908A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | CA2463850A1 Remodeling of tissues and organs |
| 04/24/2003 | CA2463754A1 Concomitant oral and topical administration of anti - infective agents |
| 04/24/2003 | CA2463711A1 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 04/24/2003 | CA2463687A1 Cyclodextrin complexes |
| 04/24/2003 | CA2463682A1 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | CA2463674A1 Controlled release capsules for providing both pulsed burst and controlled release of drugs to the rumen of ruminant animals over an extended time period |
| 04/24/2003 | CA2463672A1 Direct targeting binding proteins |
| 04/24/2003 | CA2463655A1 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | CA2463579A1 Treatment of cns disorders using cns target modulators |
| 04/24/2003 | CA2463578A1 Differentially expressed genes associated with obesity and type 2 diabetes |
| 04/24/2003 | CA2463492A1 Methods for the treatment of carcinoma |
| 04/24/2003 | CA2463435A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 04/24/2003 | CA2463142A1 Methods for preventing and treating bone loss with steroid compounds |
| 04/24/2003 | CA2463020A1 Use of gp130 activators in diabetic neuropathy |
| 04/24/2003 | CA2462785A1 Kinases and phosphatases |
| 04/24/2003 | CA2461836A1 Detection and treatment of intravascular lesions |
| 04/24/2003 | CA2461818A1 Treatment and diagnosis of insulin resistant states |